Trial Profile
A study to evaluate the reduced dose of abiraterone acetate with concomitant low-dose prednisone in the treatment of > or= 85 year-old patients with advanced castrate-resistant prostate cancer.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Oct 2015
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Prednisone
- Indications Prostate cancer
- Focus Therapeutic Use
- 15 Oct 2015 New trial record